BioSpace News Archive

CDI Laboratories, Inc announced that it has received a significant investment from BroadOak Capital Partners that will enable CDI Labs to meet increased demand for its HuProtTM proteome microarray autoantibody biomarker discovery product line and launch new phage display immunoprecipitation sequencing services.

Novavax, Inc. announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors.

Ionis Pharmaceuticals, Inc. and Royalty Pharma plc announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA® and Novartis’ pelacarsen for up to $1.125 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments.

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, is pleased to announce a partnership with ILC Dover, a leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical and medical device markets.

Kytopen announced it is assembling a group of experts in the diverse fields of immunology, synthetic biology, engineering, and manufacturing for its newly formed Scientific Advisory Board.

Acadia Pharmaceuticals Inc. announced the appointment of Dr. Doug Williamson as Executive Vice President, Head of Research and Development.

CardiacSense Ltd., a digital health company that developed the world’s most advanced, medically certified wearable device for monitoring vital signs announced receipt of U.S.A. Food and Drug Administration (FDA) clearance of its CSF-3 watch for measuring Beat-by-beat Heart Rate, and Oxygen Saturation of Arterial Hemoglobin (SpO2).

UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announces positive topline results from the IASOS Phase 2b study of oral orismilast in adult patients with moderate to severe psoriasis.

Minerva Biotechnologies, a private company developing 1st-in-human therapies for the treatment of solid tumor cancers, announced today that the FDA has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of metastatic breast cancers.

Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversight and strategic regulatory operations group.